Back to top

Arbutus Biopharma reacquires Greater China rights to imdusiran, forms SAB

Arbutus Biopharma (ABUS) announced that it has reacquired China rights to its lead compound, imdusiran, from Qilu Pharmaceutical. The parties have ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Arbutus Biopharma Corporation (ABUS)